Multiple Myeloma

Jason Valent, MD, oncologist, Cleveland Clinic, discusses the potential application of minimal residual disease (MRD) negativity in patients with multiple myeloma.

Sandy Wong, MD, assistant professor, University of California, San Francisco (UCSF) School of Medicine, discusses a trial with an anti-CD46 antibody in multiple myeloma.

Michael Green, MD, discusses treatment strategies following early relapse in multiple myeloma.

Among new advances in multiple myeloma, high-dose chemotherapy and allogeneic stem cell transplant remain the go-to frontline treatment for patients with newly diagnosed multiple myeloma.

The FDA has granted a priority review to a new drug application for selinexor for the treatment of patients with penta-refractory multiple myeloma.

Thomas G. Martin, MD, discusses the clinical utility of autologous stem cell transplantation and the rapidly evolving treatment paradigm of myeloma.

Bita Fakhri, MD, MPH, shares her insight on the treatment of patients with newly diagnosed multiple myeloma.

Michael Green, MD, Northern California Oncologist, discusses early relapse in multiple myeloma.

The FDA has approved the next-generation sequencing assay clonoSEQ as a test for minimal residual disease (MRD) in patients with acute lymphoblastic leukemia or multiple myeloma.

Noopur Raje, MD, director, Center for Multiple Myeloma, Massachusetts General Hospital, discusses the potential of quadruplet regimens in the multiple myeloma treatment paradigm.

The FDA has approved a once-weekly dosing option of carfilzomib to use in combination with dexamethasone for patients with relapsed/refractory multiple myeloma.

Jeffrey Zonder, MD, associate professor of oncology and medicine, Barbara Ann Karmanos Cancer Institute, Wayne State University, discusses induction therapy in the treatment of patients with newly diagnosed multiple myeloma.

Deepu Madduri, MD, assistant professor, Mount Sinai Hospital, discusses the use of checkpoint inhibitors in multiple myeloma.

Andrew Kin, MD, shares his insight on the treatment landscape for multiple myeloma and the challenges that remain.

Andrew Kin, MD, assistant professor, Karmanos Cancer Institute, discusses triplet regimens for the treatment of patients with relapsed multiple myeloma.

Results of the phase IIb STORM trial demonstrated that the combination of selinexor and dexamethasone demonstrated promising clinical activity in patients with penta-refractory multiple myeloma, a population that currently has no standard-of-care regimen.

Updated safety data of the ASPIRE and ENDEAVOR trials showed that carfilzomib-based (Kyprolis) regimens demonstrate benefit across patient populations of multiple myeloma.

Alexander M. Lesokhin, MD, assistant attending, Department of Medicine and Myeloma Service, Memorial Sloan Kettering Cancer Center, discusses the current treatment landscape for patients with multiple myeloma.

Kenneth H. Shain, MD, PhD, discusses the evolution of treatment for patients with newly diagnosed multiple myeloma and how physicians are leveraging data with chimeric antigen receptor T-cell therapy and minimal residual disease negativity to improve outcomes.

Noopur Raje, MD, director, Center for Multiple Myeloma, Massachusetts General Hospital Cancer Center, discusses the impact of bb2121 in myeloma.

Rachid Baz, MD, discusses the ARROW, ELOQUENT-3, and OPTIMISMM studies and highlights others that are demonstrating equally impressive response rates in patients with relapsed/refractory multiple myeloma.

Andrew L. Pecora, MD, discusses the use of autologous stem cell transplantation in patients aged ≥75 years and the future of care in multiple myeloma.

Francesca Gay, MD, PhD, discusses the FORTE trial comparing carfilzomib plus lenalidomide and dexamethasone versus carfilzomib plus cyclophosphamide and dexamethasone in newly diagnosed patients with multiple myeloma.

Rachid Baz, MD, associate member, head of the Myeloma Section at Moffitt Cancer Center, discusses the potential use of selinexor (KPT-330) in patients with multiple myeloma.

Kenneth H. Shain, MD, PhD, assistant member, Moffitt Cancer Center, discusses novel agents in multiple myeloma.